Mestinon (Pyridostigmine Bromide) Patent Expiration, LOE Window & CMS Spending

Mestinon (Pyridostigmine Bromide) by Bausch Health: Off-Patent Genericized (AB Competition), 6 AB generics, $9.8M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN009829 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$9.8M
2024 Medicare Part D Spend$7.8M
2024 Medicaid Spend$2.0M
Reported Wholesale Price Change (CA SB 17)15 WAC filings (max 32.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.